On Friday, Pfizer lowered its earnings forecast for 2006. Wall Street was looking for $2.03 a share, but the company is only expecting $2 a share. Last year’s earnings came in at $2.02 a share.
Merck could be a good buy in a year or so, but I still wouldn’t touch either of these stocks.
MRK, PFE 1-yr Stock Performance